Shilajit evidence rests on purified standardized extracts, not raw resin. Moderate-quality human studies support higher testosterone in middle-aged men, better strength under fatigue, signs of collagen building, and bone density preservation in postmenopausal women with low bone mass. Main risk is heavy metals and thallium in poorly processed products. Practical use: 250–500 mg/day purified extract when purity is verified. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Total testosterone | Age/sex-specific functional targets | Tracks androgen response |
| Free testosterone | Lab-method-specific; interpret with total testosterone | Bioavailable androgen fraction |
| DHEAS | Age/sex reference; watch large upward swings | Rose with purified shilajit in RCT |
| CBC / hematocrit | Hematocrit roughly 40–50% men (individualize) | Androgen-driven erythrocytosis risk |
| Comprehensive metabolic panel (CMP) | Standard; eGFR at age-appropriate function | Hepatic/renal safety |
| hsCRP | Often <1.0 mg/L functional goal | Inflammation trend |
| 25-OH vitamin D | Often 40–60 ng/mL functional discussion range | Bone and hormone milieu |
| DXA BMD (if osteopenia indication) | T-score goals individualized | Primary structural outcome in bone trial |
| Heavy metals panel (Pb, As, Hg, Cd ± Tl) | Below clinical concern thresholds | Detect product contamination |
Cadence: Baseline; 8–12 weeks after initiation; then every 6–12 months if continued (earlier if symptoms or high-risk concurrent hormone-active use)